Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer Clinical research trials and Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer. Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer clinical trial. Human subjects frequently get the finest healthcare available for their Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.

Home > "S" Clinical Trials Conditions > Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer



Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

For Condition: Peritoneal Cancer,Fallopian Cancer,Ovarian Cancers
Status: Terminated
Sponsor(s): Sponsor Name Pending ,
Synopsis: The purpose of this research study is to determine the effectiveness of the drug, topotecan, given intravenously (into a vein) together with the drug gemcitabine in patients with recurrent platinum-sensitive ovarian, fallopian or primary peritoneal cancer, as well as tumors of mixed mullerian origin. Additional purposes are to determine the long term outcome and side effects of this combination treatment. Since topotecan and gemcitabine have different mechanisms of action, the combination of these 2 drugs may provide better results than either drug alone. Prior studies suggest that the combination of topotecan and gemcitabine improves the effects on the tumor and also appeared to be well tolerated.
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Open Label, Uncontrolled, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: (patients must meet the following criteria in order to be eligible for this study) - One prior platinum-based chemotherapy regimen for the treatment of primary disease. - Patients re-challenged with the same or one component of their first regimen are still eligible. - At least 4 weeks since last surgery or radiation therapy. - Must have had a treatment-free interval of greater than 6 months following response to platinum.
Total Enrollment: 

Location and Contact Information:

Study Site
Vancouver,  British Columbia,  V5Z 4E6
Canada
 

Study Site
Abington,  Pennsylvania,  19001-3788
United States
 

Study Site
Hattiesburg,  Mississippi,  39401
United States
 

Study Site
Toronto,  Ontario,  M4N 3M5
Canada
 

Study Site
Phoenix,  Arizona,  85006
United States
 

Study Site
Morristown,  New Jersey,  07960
United States
 

Study Site
Ottawa,  Ontario,  K1H 8L6
Canada
 

Study Site
Hinsdale,  Illinois,  60521
United States
 

Study Site
Columbus,  Georgia,  31902
United States
 

Study Site
Rochester,  New York,  14620
United States
 

Study Site
Puyallup,  Washington,  98372
United States
 

Study Site
Detroit,  Michigan,  48202
United States
 

Study Site
Sunrise,  Florida,  33323
United States
 

Study Site
Chapel Hill,  North Carolina,  27599-7570
United States
 

Study Site
Southfield,  Michigan,  48075
United States
 

Study Site
Calgary,  ,  T2N 4N2
Canada
 

Study Site
Rockville Centre,  New York,  11570
United States
 

Study Site
Los Gatos,  California,  95032
United States
 

Study Site
Lansing,  Michigan,  48912
United States
 

Study Site
Chattanooga,  Tennessee,  37403
United States
 

Study Site
Santa Rosa,  California,  95403
United States
 

Study Site
Washington D.C.,  District of Columbia,  20010
United States
 

Study Site
Greenville,  South Carolina,  29605
United States
 

Study Site
St. Louis,  Missouri,  63117
United States
 


Additional Information:
Study ID Numbers:
  104864/627; 
Study Start Date: 
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00061308

Other Ovarian Cancers Studies:
1. Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

Related Studies:

Other Ovarian Cancers Clinical Trials
Other Tennessee Clinical Trials
Other Chattanooga Clinical Trials

Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

Modify your Search

  Other Ovarian Cancers Clinical Trials
  Other Tennessee Clinical Trials
  Other Chattanooga Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103